Edition:
United States

Insmed Inc (INSM.OQ)

INSM.OQ on NASDAQ Stock Exchange Global Select Market

20.31USD
4:00pm EDT
Change (% chg)

$0.86 (+4.42%)
Prev Close
$19.45
Open
$19.30
Day's High
$20.32
Day's Low
$19.04
Volume
287,402
Avg. Vol
238,088
52-wk High
$33.94
52-wk Low
$18.67

Latest Key Developments (Source: Significant Developments)

Insmed Reports Q4 Loss Per Share $0.85
Friday, 23 Feb 2018 07:30am EST 

Feb 23 (Reuters) - Insmed Inc ::INSMED REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.85.AS OF DEC 31, 2017, INSMED HAD CASH AND CASH EQUIVALENTS OF APPROXIMATELY $381.2 MILLION AND DEBT OF $55.0 MILLION.ON TRACK TO FILE NDA BEFORE END OF MARCH AND ANTICIPATE A PRIORITY REVIEW.EXPECTS CASH BASED OPERATING EXPENSES, CAPITAL , OTHER CASH INVESTMENTS TO BE IN RANGE OF $145 MILLION TO $165 MILLION FOR FIRST HALF OF 2018.Q4 EARNINGS PER SHARE VIEW $-0.64 -- THOMSON REUTERS I/B/E/S.  Full Article

Insmed Prices Public Offering Of $400 Mln Principal Amount Of Its Convertible Senior Notes
Tuesday, 23 Jan 2018 10:48pm EST 

Jan 24 (Reuters) - Insmed Inc ::INSMED ANNOUNCES PRICING OF PUBLIC OFFERING OF CONVERTIBLE SENIOR NOTES.INSMED INC - ‍PRICED ITS REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $400 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS 1.75% CONVERTIBLE SENIOR NOTES DUE 2025​.  Full Article

Insmed Announces Proposed Public Offering Of Convertible Senior Notes
Monday, 22 Jan 2018 04:07pm EST 

Jan 22 (Reuters) - Insmed Inc ::INSMED ANNOUNCES PROPOSED PUBLIC OFFERING OF CONVERTIBLE SENIOR NOTES.INSMED INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $300 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2025.  Full Article

Insmed Announces Additional Data From ALIS Phase 3 Clinical Program
Wednesday, 3 Jan 2018 04:09pm EST 

Jan 3 (Reuters) - Insmed Inc ::INSMED ANNOUNCES ADDITIONAL DATA FROM ALIS (AMIKACIN LIPOSOME INHALATION SUSPENSION) PHASE 3 CLINICAL PROGRAM FOR ADULT PATIENTS WITH TREATMENT REFRACTORY NTM LUNG DISEASE CAUSED BY MAC AND REPORTS PROGRESS WITH COMMERCIAL PREPARATIONS.INSMED INC - COMPANY TARGETING SUBMISSION OF NDA BEFORE END OF MARCH.INSMED - REGULATORY ACTIVITIES AND PRE-COMMERCIAL EXPANSION ONGOING TO SUPPORT ANTICIPATED US COMMERCIAL LAUNCH OF ALIS IN LATE 2018.INSMED INC - ‍REMAINS ON TRACK TO FILE ITS NDA FOR ACCELERATED APPROVAL OF ALIS WITH U.S. FDA BEFORE END OF MARCH​.INSMED - INS-312 DATA SHOWS 28% PATIENTS EARLIER GOT 6 MONTHS OF GBT ALONE ACHIEVED CULTURE CONVERSION AFTER ADDITION OF ALIS TO THERAPY.INSMED INC - ‍PLANS TO RECONFIRM WITH PMDA APPROVAL PATH FOR ALIS IN JAPAN BASED ON CLINICAL DATA​.INSMED INC - ‍PLANS TO FILE AN APPLICATION WITH PMDA IN LATE 2018 OR EARLY 2019​.  Full Article

Insmed Q3 loss per share $0.69
Thursday, 2 Nov 2017 07:30am EDT 

Nov 2 (Reuters) - Insmed Inc :Insmed reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.69.Q3 earnings per share view $-0.69 -- Thomson Reuters I/B/E/S.  Full Article

Insmed announces proposed public offering of common stock
Tuesday, 5 Sep 2017 04:01pm EDT 

Sept 6 (Reuters) - Insmed Inc :Insmed announces proposed public offering of common stock.Insmed Inc - ‍Has commenced an underwritten public offering of $250 million of shares of its common stock​.Insmed - Intends to use net proceeds from offering to fund ongoing and future clinical development of amikacin liposome inhalation suspension, among the others.  Full Article

Insmed announces positive top-line results from phase 3 convert study of ALIS
Tuesday, 5 Sep 2017 07:00am EDT 

Sept 5 (Reuters) - Insmed Inc :Insmed announces positive top-line results from phase 3 convert study of ALIS (amikacin liposome inhalation suspension) in adult patients with treatment-refractory nontuberculous mycobacterial (NTM) lung disease caused by mycobacterium avium complex (MAC).Study met primary endpoint of culture conversion (p< 0.0001)​.Positive top-line results from global phase 3 controlled study in patients with NTM, a rare, progressive, destructive lung infection​.Company plans to pursue accelerated approval and request priority review​.Plans to pursue accelerated approval of ALIS under subpart H based on data from convert study, which will be reviewed by division of anti-infective products​.Company also reported top-line data for several secondary endpoints as of 6-month timepoint​.Top-line data for 6-minute walk test indicates no statistically significant difference between patients in two arms​.Company is continuing its analysis of impact of conversion on a variety of other clinical measures​.  Full Article

Insmed reports Q2 loss per share $0.72
Thursday, 3 Aug 2017 07:30am EDT 

Aug 3 (Reuters) - Insmed Inc ::Insmed reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.72.Q2 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.Insmed Inc - ‍on track to report top-line results from phase 3 convert study in September plus or minus one month​.Insmed Inc - ‍plan to initiate enrollment of phase 2 dose-ranging study of INS1007 in non-cystic fibrosis (non-CF) bronchiectasis in H2 2017​.  Full Article

Insmed Inc files for potential stock shelf offering
Friday, 19 May 2017 04:35pm EDT 

May 19 (Reuters) - Insmed Inc :Files for potential stock shelf offering; size not disclosed - SEC filing.  Full Article

Insmed appoints Paolo Tombesi CFO, effective June 1, 2017
Monday, 15 May 2017 07:00am EDT 

May 15 (Reuters) - Insmed Inc :Insmed announces key additions to its executive management team.Insmed inc says appointment of Paolo Tombesi as chief financial officer, effective June 1, 2017.Insmed inc says additionally, Eugene Sullivan has been appointed to newly created role of chief product strategy officer.  Full Article

BRIEF-Insmed Announces FDA Acceptance For Filing Of NDA For Lung Disease Treatment

* INSMED ANNOUNCES FDA ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION FOR ALIS IN NTM LUNG DISEASE CAUSED BY MAC